335256-12-7

Basic information

• Product Name: 5-cyano-2-fluorobenzoyl chloride
• Synonyms: 5-cyano-2-fluorobenzoyl chloride
• CAS NO: 335256-12-7
• Molecular Weight: 183.569
• Mol File: 335256-12-7.mol

Chemical Properties

• CAS DataBase Reference: 5-cyano-2-fluorobenzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 5-cyano-2-fluorobenzoyl chloride(335256-12-7)
• EPA Substance Registry System: 5-cyano-2-fluorobenzoyl chloride(335256-12-7)

Safety Data

• Hazardous Substances Data: 335256-12-7(Hazardous Substances Data)

Upstream product

• 146328-87-2 2-fluoro-5-cyanobenzoic acid 
• 7304-32-7 2-fluoro-5-nitrobenzoic acid 

Downstream Products

• 1217420-11-5 N-{(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}-5-cyano-2-fluorobenzamide 
• 856931-47-0 4-fluoro-3-(hydroxymethyl)benzonitrile 
• 856935-35-8 3-(bromomethyl)-4-fluorobenzonitrile 
• 1217421-01-6 N-[(3E)-5-tert-butyl-1-methyl-2-(tetrahydro-2H-pyran-4-ylmethyl)-1,2-dihydro-3H-pyrazol-3-ylidene]-5-cyano-2-fluorobenzamide 
• 335256-08-1 3-(5-cyano-2-fluoro-phenyl)-3-oxo-propionic acid ethyl ester 

Relevant articles and documents

Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors

A series of novel quinazoline derivatives bearing various C-6 benzamide substituents were synthesized and evaluated as EGFR inhibitors, and most showed significant inhibitory potency against EGFR kinase. In particular, compound 6g possessed potent inhibitory activity against EGFR wild-type (IC50 = 5 nM), and strong antiproliferative activity against HCC827 and Ba/F3 (L858R) cell lines. Kinase profiling against a panel of 365 kinases showed that 6g was highly selective for EGFR. Furthermore, 6g showed desirable properties in assays of liver microsome metabolic stability and cytochromes P450 inhibition and preliminary pharmacokinetic study. The overall attractive profile of 6g made it an interesting compound for further development.

Novel pyrazolo[1,5-a]pyridines with improved aqueous solubility as p110α-selective PI3 kinase inhibitors

As part of our investigation into pyrazolo[1,5-a]pyridines as novel p110α selective PI3 kinase inhibitors, we report a range of analogues with improved aqueous solubility by the addition of a basic amine. The compounds demonstrated comparable p110α potency and selectivity to earlier compounds but with up to 1000× greater aqueous solubility, as the hydrochloride salts. The compounds also displayed good activity in a cellular assay of PI3 kinase activity.

N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS

A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS

The present application relates to cannabinoid receptor ligands of formula (I) wherein X1, A1, Rx, R2, R3, R4, and z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions.

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS

Disclosed herein are cannabinoid receptor ligands of formula (I) wherein A1, A5, Rx, X4, and z are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS

Disclosed herein are compounds of formula (I) wherein Ring A and R1 are as defined in the specification. Pharmaceutical compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and pharmaceutical compositions are also disclosed.